TCH Plus Pertuzumab (TCHP) Protocol for HER2-Positive Breast Cancer
The TCHP regimen consists of docetaxel 75 mg/m² IV and carboplatin AUC 6 IV on day 1 of each 21-day cycle for 6 cycles, with concurrent pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks), all administered on day 1 of each cycle. 1
Standard Dosing Schedule
Cycle 1 (Day 1):
- Pertuzumab: 840 mg IV loading dose 2
- Trastuzumab: 8 mg/kg IV loading dose 1
- Docetaxel: 75 mg/m² IV 1
- Carboplatin: AUC 6 IV 1
Cycles 2-6 (Day 1 of each 21-day cycle):
All medications are administered intravenously on day 1, with cycles repeated every 21 days for a total of 6 cycles. 1
Post-Chemotherapy HER2-Targeted Therapy
After completing 6 cycles of TCHP, continue trastuzumab 6 mg/kg IV every 3 weeks (with or without pertuzumab 420 mg IV every 3 weeks) to complete 1 year total of HER2-targeted therapy. 1, 3
- In the adjuvant setting with node-positive disease after neoadjuvant therapy with residual disease, dual HER2 blockade (trastuzumab + pertuzumab) is category 1 recommended 3
- For patients without residual disease or no preoperative therapy, trastuzumab alone (category 1) ± pertuzumab is appropriate 3
Cardiac Monitoring Requirements
Perform cardiac function assessment (echocardiogram or MUGA scan) at baseline, 3 months, 6 months, and 9 months during therapy. 1
- Baseline left ventricular ejection fraction must be ≥55% before initiating therapy 4
- The TCHP regimen avoids anthracycline-related cardiotoxicity while maintaining efficacy 5
Clinical Efficacy Data
Real-world evidence demonstrates pathological complete response (pCR) rates of 62-66% with TCHP in HER2-positive early breast cancer. 6, 7
- The modified dose carboplatin regimen (AUC 5-6) shows similar efficacy with manageable toxicity 7
- Three-year event-free survival reaches 90.6% with TCHP 6
- pCR rates are lower in hormone receptor-positive subgroups (approximately 50%) compared to hormone receptor-negative disease (70-80%) 2
Common Toxicities and Management
The most frequent adverse events include anemia (90%), mucositis (85%), pain (83%), and diarrhea (71%). 6
- Grade 3-4 toxicity occurs in approximately 30-38% of patients 8, 7
- Anemia frequently requires transfusion support 6
- Neuropathy occurs in approximately 13% (grade 3-4) with standard dosing 8
- Nausea and diarrhea are common but manageable with supportive care 8, 6
Important Clinical Considerations
TCHP is preferred over anthracycline-containing regimens for patients at higher risk of cardiotoxicity. 5
- The regimen avoids concurrent anthracycline and trastuzumab administration, which significantly increases cardiac toxicity 3, 5
- Completion rates are high, with most patients (78-100%) finishing all planned therapy without early discontinuation 6, 7
- Dose reductions occur in approximately 22% of patients but do not significantly compromise efficacy 7